SCHEMBL1721136

SCHEMBL1721136

CCSc1nc2cc(C(F)(F)F)ccc2c(C)c1C(=O)NCc1ccncc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.49
NAMPT P43490 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
HSD17B10 Q99714 1/20 0.42
GSK3B P49841 1/20 0.42
FLT1 P17948 3/20 0.41
KDR P35968 3/20 0.41
TACR1 P25103 1/20 0.41
GAA P10253 1/20 0.41
PDE4A P27815 3/20 0.41
PDE4B Q07343 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4D Q08499 3/20 0.41
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
ELANE P08246 1/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721222 0.96 SORT1 (0.43) SORT1NAMPTTACR1KDM4EPTGER4
SCHEMBL1722065 0.92 TACR1 (0.48) SORT1TACR1ALDH1A1KDM4EPTGER4
SCHEMBL1721672 0.92 LMNA (0.42) SORT1SMN1; SMN2TACR1HPGDLMNA
SCHEMBL1722444 0.91 SMN1; SMN2 (0.43) SORT1SMN1; SMN2TACR1GAAALDH1A1
SCHEMBL1721202 0.91 MTOR (0.43) SORT1TACR1KDM4EPTGER4
SCHEMBL1721504 0.91 EPHX2 (0.43) SORT1TACR1MEN1CYP1A2CYP2C19
SCHEMBL1722120 0.91 CNR1 (0.46) TACR1HPGDLMNAMEN1CYP1A2
SCHEMBL1721824 0.90 SORT1 (0.52) SORT1NAMPTSMN1; SMN2GAAHPGD
SCHEMBL1721270 0.90 TACR1 (0.43) SORT1NAMPTTACR1HPGDALDH1A1
SCHEMBL1722435 0.90 MLYCD (0.48) TACR1GAAHPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US claimed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US claimed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP claimed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO claimed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US claimed
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US disclosed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US disclosed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP disclosed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO disclosed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS KCNQ1, KCNQ2, KCNJ2 SORT1 4710/4885NAMPT 932/4885SMN1; SMN2 4161/4885
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators KCNQ1, KCNQ2, KCNJ2 SORT1 4710/4885NAMPT 932/4885SMN1; SMN2 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.